Skip to main content
Fig. 2 | BMC Cardiovascular Disorders

Fig. 2

From: Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis

Fig. 2

Deterministic sensitivity analysis of patient-care strategies. The incremental costs and incremental QALYs were assessed for a cohort of 100,000 patients using the upper range (red bar) and lower range (blue bar) of each parameter while keeping all other parameters at their base-case value. The results for the 10 parameters that caused the largest changes are reported. Panel a Incremental costs for test-and-HST vs. MST; Panel b Incremental QALYs for test-and-HST vs. MST; Panel c Incremental costs for test-and-MST vs. do-not-treat; Panel d Incremental QALYs for test-and-MST vs. do-not-treat; Panel e Incremental costs for HST vs. MST; Panel f Incremental QALYs for HST vs. MST

Back to article page